On November 6, 2024, Stuart Tross, Chief People & Workpl Officer of MannKind Corp (MNKD, Financial), executed a sale of 55,000 shares of the company at a price of $7.34 per share. This transaction was reported in a recent SEC Filing. Following this sale, the insider now owns 967,191 shares of MannKind Corp.
MannKind Corp focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.
Over the past year, the insider has sold a total of 160,000 shares and has not made any purchases. The company has observed a pattern of 13 insider sells and no insider buys over the same period.
Shares of MannKind Corp were trading at $7.34 on the day of the sale, giving the company a market cap of approximately $2.03 billion. The price-earnings ratio stands at 146.90, significantly above both the industry median of 27.135 and the company's historical median.
The GF Value of MannKind Corp is $10.73, indicating a price-to-GF-Value ratio of 0.68. This suggests that the stock might be a possible value trap, and potential investors should think twice before making an investment.
The GF Value is calculated based on historical trading multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor which considers past returns and growth, and future business performance estimates from Morningstar analysts.
This insider sale might provide current shareholders and potential investors with important cues about the company's valuation and future performance expectations.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
